AbbVie ABBV-295 Phase 1 Data Show Long-Acting Potential for Obesity Treatment at EASD 2026
AbbVie has presented detailed Phase 1 data for ABBV-295 at EASD 2026, demonstrating meaningful body weight reduction, favorable tolerability and an approximately 11–12-day half-life. The investigational long-acting amylin analog is advancing toward Phase 2 development for chronic weight management, with potential dosing intervals extending beyond weekly administration.
Novo Nordisk Reports CagriSema EASD 2026 Data Showing Reduced ‘Food Noise’ and Organ and Bone Health Benefits
Novo Nordisk presented CagriSema EASD 2026 data showing changed brain responses to food cues, reduced ‘food noise’, less fat around abdominal organs and preliminary bone reassurance in adults with obesity or type 2 diabetes.
Roche Fenebrutinib FDA Filing Accepted Under Priority Review for Relapsing and Primary Progressive Multiple Sclerosis.
The Roche fenebrutinib FDA filing has been accepted under priority review for relapsing and primary progressive multiple sclerosis. The application draws on the FENhance 1, FENhance 2 and FENtrepid Phase III studies.
Novo Ozempic 2 mg MACE Analysis Shows 6% Lower Cardiovascular Risk Versus Switching to Mounjaro at EASD 2026
Novo presented COMPETE SWITCH CV real-world data at EASD 2026. Adults with type 2 diabetes who escalated from Ozempic 1 mg to 2 mg were associated with a 6% lower MACE risk than those who switched to Mounjaro.
AbbVie Valkai AI Partnership Deploys Purpose-Built AI Across Targeted Clinical Development Areas
AbbVie (NYSE: ABBV) has entered a new collaboration with life sciences AI platform Valkai to apply purpose-built AI across targeted areas of clinical research, aiming to generate insights faster and support shorter development timelines.
Novo HRS-1596 License: Novo Secures Hengrui Pharma’s Oral Once-Weekly GLP-1/GIP Agonist in Deal Worth Up to $2.6 Billion
Novo Nordisk HRS-1596 is the focus of a new exclusive license with Hengrui Pharma worth up to $2.6 billion, including $300 million upfront. The phase 1-ready GLP-1/GIP dual agonist has potential for once-weekly oral dosing.
Merck SPR2015 KRAS G12D Inhibitor Deal Strengthens Oncology Pipeline Through $2.13 Billion Agreement
Merck has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor, in a transaction valued at up to $2.13 billion, including a $400 million upfront payment.
AbbVie JUVMO (Tavapadon) Wins FDA Approval as First Selective D1/D5 Receptor Agonist for Parkinson’s Disease
AbbVie JUVMO (tavapadon) has received FDA approval as the first selective D1/D5 receptor agonist for adults with Parkinson’s disease. AbbVie expects U.S. availability in October 2026.
Merck Ifinatamab Deruxtecan BLA Withdrawn in Previously Treated ES-SCLC
Merck and Daiichi Sankyo have voluntarily withdrawn the U.S. Biologics License Application for ifinatamab deruxtecan in certain patients with previously treated extensive-stage small cell lung cancer after discussions with the FDA indicated that the submitted data did not meet the requirements for accelerated approval.
Eli Lilly Olumiant Alopecia Areata Treatment Approved by FDA for Pediatric Patients 12 and Older
Lilly Olumiant Alopecia Areata has received FDA approval for pediatric patients 12 and older, expanding treatment access based on Phase 3 BRAVE-AA-PEDS trial results showing substantial scalp hair regrowth in adolescents with severe alopecia areata.